The value of integrated team-based delivery models-incorporating physical and mental health care in a primary care setting-is not established. Reiss-Brennan and colleagues evaluated the association of integrated team-based care with measures of health care quality, utilization, and cost in a retrospective cohort of 113 452 patients enrolled in 102 primary care practices of an integrated health care system. The authors found that compared with traditional care model practices, receipt of care in integrated team-based care practices was associated with higher rates of some measures of care quality, lower rates for some measures of acute care utilization, and lower actual payments received by the health delivery system. In an Editorial, Schwenk discusses resource utilization and costs of integrated behavioral and primary care health systems.
RNA Biosignatures of Bacterial Infection in Febrile Infants 846
In an observational cohort of 279 febrile infants aged 60 days or younger who presented to 22 emergency departments over 2 years, Mahajan and colleagues assessed whether microarray assays to measure markers of host response to pathogens-refl ected in RNA biosignatures-could provide an alternative to culture-based diagnosis to distinguish infants with serious bacterial infections from those not infected. The authors report identification of unique RNA biosignatures that discriminated between infants with and without bacterial infections. 
High Cost of Prescription Drugs in the United States 858
The rising cost of prescription drugs in the United States is a growing concern. In a review of the literature (January 2005-July 2016), Kesselheim and colleagues examined determinants of US drug prices, justifi cation for the pricing decision, and consequences for patients and payers. The evidence reviewed suggests that high drug prices are the result of market exclusivity-awarded at the time of US Food and Drug Administration approvalcombined with drug coverage requirements imposed on government payers. The authors found no evidence of an association between research and development costs and prices; rather, drug prices are based on what the market will bear. Solutions to high drug costsincluding enhanced competition, more opportunities for price negotiation, and provision of information on cost-eff ectiveness of therapeutic alternatives-are discussed.
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Time in Therapeutic Range During Warfarin Treatment 872
An article in JAMA Cardiology reported that among Swedish patients with nonvalvular atrial fi brillation, those well-managed while taking warfarin therapy (defi ned as mean time in therapeutic range [iTTR] ≥70%) had a lower risk of complications than patients with an iTTR less than 70%. In this From The JAMA Network article, Passman discusses factors to consider when initiating anticoagulation therapy in this patient population.
Antiviral Agents in Early Treatment of Bell Palsy 874
The role of antiviral drugs in the early management of acute idiopathic facial nerve paralysis (Bell palsy) is not clear. This JAMA Clinical Evidence Synopsis article summarizes a Cochrane review of 8 randomized trials (1315 patients total) that compared outcomes among patients who presented within 72 hours of Bell palsy symptoms and were prescribed either oral antiviral therapies plus oral corticosteroids or oral corticosteroids alone. Combination therapy resulted in a higher proportion of patients who recovered after 3 to 12 months. 
